Stoke Therapeutics to Present at June Investor Conferences

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology firm headquartered in Bedford, Massachusetts, is advancing the treatment of severe genetic diseases by developing RNA-based medicines aimed at increasing protein expression. The company recently announced its participation in two upcoming investor conferences.

The first event is the Goldman Sachs 45th Annual Global Healthcare Conference, scheduled for Monday, June 10, 2024, at 4:00 p.m. ET. The second event is the TD Cowen Genetic Medicines & RNA Summit, set for Thursday, June 20, 2024, at 10:00 a.m. ET. Both presentations will be available via live webcasts, and archived replays will be accessible on the Stoke Therapeutics website in the Investors & News section.

Stoke Therapeutics employs a proprietary technology called TANGO (Targeted Augmentation of Nuclear Gene Output) to develop antisense oligonucleotides (ASOs). These ASOs are designed to selectively restore normal protein levels in patients suffering from various genetic conditions caused by haploinsufficiency, where a 50% reduction in normal protein levels leads to disease.

Stoke's leading therapeutic candidate, STK-001, is currently undergoing clinical trials for the treatment of Dravet syndrome. This severe and progressive genetic epilepsy is one of many conditions caused by haploinsufficiency. Additionally, Stoke is developing STK-002 for autosomal dominant optic atrophy (ADOA), the most common inherited disorder affecting the optic nerve.

Beyond these initial focus areas, Stoke Therapeutics is exploring the application of its TANGO approach in other organs, tissues, and systems, demonstrating the broad potential of their technology. The company believes that their innovative method could address a wide range of genetic diseases beyond their current focus on the central nervous system and ocular conditions.

Stoke Therapeutics operates from its headquarters in Bedford, Massachusetts, with additional offices located in Cambridge, Massachusetts. The company is committed to advancing medical science and improving the quality of life for patients suffering from severe genetic diseases through its cutting-edge RNA-based treatments.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!